USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
BIOPROTECTION SYSTEMS CORP.
Address:
2901 S LOOP DR STE 3360
Ames, IA
Phone:
(515) 296-3819
URL:
N/A
EIN:
202844633
DUNS:
606727076
Number of Employees:
60
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $769,885.00 3
SBIR Phase II $749,626.00 1

Award List:

Multiple Indication Adjuvants

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$69,990.00
Agency / Branch:
DOD / CBD
Principal Investigator:
Ramon Flick, Senior Director of Vaccine Developm
Abstract:
The objective of this study is to demonstrate the efficacy and broad applicability of the human immune-modulating alphaGal Adjuvant Technology for antiviral vaccine development. We will use viral vaccine candidates for the select Category A viral pathogens Zaire ebolavirus (ZEBOV, filovirus), Rift… More

Improved Venezuelan equine encephalitis virus vaccines

Award Year / Program / Phase:
2009 / SBIR / Phase II
Award Amount:
$749,626.00
Agency / Branch:
DOD / CBD
Principal Investigator:
Ramon Flick, Acting Chief Scientific O
Abstract:
We hypothesize that the application of the broad-spectrum immune-stimulatory and -modulatory HyperAcute alphaGal Adjuvant Technology will enhance the potency and effectiveness of VEEV vaccine candidates. To complement the exciting preclinical and clinical results obtained with alphaGal-modified… More

Development of Multivalent Vaccines Against Yellow Fever and Arena Viruses

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$599,895.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Indigenous population, travelers and troops present in Africa and South America are clearly at risk of exposure to several arenaviruses. Several human pathogenic arenaviruses, e.g., Lassa and Junin viruses, are listed o n the NIAID's Priority Pathogens and CDC's… More

Development of a safe and efficacious vaccine for Rift Valley fever virus

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
USDA
Principal Investigator:
Ramon Flick, Chief Science Officer – (515) 598-5017
Abstract:
This application addresses the USDA NIFA "Global Food Security and Hunger" primary societal challenge area by developing a countermeasure against a potential agricultural disease threat - Rift Valley fever virus (RVFV). RVFV is an arthropod-borne pathogen that often results in severe… More